NCT06622824View on ClinicalTrials.gov

To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

756

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

October 20, 2027

Study Completion Date

June 30, 2028

Conditions
Androgenetic Alopecia (AGA)
Interventions
DRUG

KX-826 0.5% BID

0.5% of the investigational drug KX-826 to be applied topically to scalp twice daily for 24 weeks

DRUG

KX-826 1.0% BID

1.0% of the investigational drug KX-826 to be applied topically to scalp twice daily for 24 weeks

DRUG

Vehicle (Placebo) applied BID

Matching placebo applied topically to scalp twice daily for 24 weeks

Trial Locations (1)

Unknown

Peking University People's Hospital, Beijing

All Listed Sponsors
collaborator

Suzhou Koshine Biomedica, Inc.

INDUSTRY

lead

Suzhou Kintor Pharmaceutical Inc,

INDUSTRY